Alcon Launches Clareon PanOptix Pro Trifocal IOL

Alcon has introduced the Clareon PanOptix Pro IOL in the US.

from Eyewire

According to Alcon, PanOptix Pro leverages proprietary ‘ENLIGHTEN NXT’ Optical technology, which is designed to deliver the highest reported light utilization of any trifocal IOL—and the lowest light scatter. [1-3,6-10]. These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.[1,†] PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and high patient satisfaction of PanOptix.[1,2,11,12]

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” Rob Scott, VP, Intraocular Devices, R&D, Alcon, said in a company news release. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”

PanOptix Pro will be the first presbyopia-correcting IOL available in the US from Alcon in the single-use Clareon AutonoMe preloaded delivery system. The IOL will also be available for use with the Clareon Monarch IV delivery system beginning in 2026. PanOptix Pro offers powers ranging from +6.0 through +30.0 D (in 0.5 D increments), +31.0 through +34.0 D (in 1.0 D increments), with a +2.17 D intermediate and a +3.25 D near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.

“We did have patients in the past talk about low light and maybe how they had some contrast issues because when you have a trifocal lens, you’re splitting light, and when you’re splitting light, you have light scatter,” Nicole Fram, MD, Managing Partner at Advanced Vision Care in Los Angeles, was among the first U.S. surgeons to implant the PanOptix Pro, said in an interview with Eyewire News. “And to tell you the truth, I didn’t know that there was going to be this ‘wow’ factor and I was really impressed with how patients felt after. You’re getting that ‘wow’ factor that you would get from a monofocal lens plus having this spectacle independence.

PanOptix Pro has been introduced to select practices across the US, with broad commercial availability in May. Additional markets will begin rollout in late 2025.

For surgeons interested in more information on PanOptix Pro, visit MyAlcon.com or visit the Alcon Booth #1815 at the American Society of Cataract and Refractive Surgery annual meeting (Los Angeles, April 25-28).